GHIT Fund reinforces its support to DNDi leishmaniasis and Chagas disease projects
GHIT Fund reinforces its support to DNDi leishmaniasis and Chagas disease projects
DNDi is very pleased to announce the renewed commitment of the Global Health Innovative Technology Fund (GHIT), its donor since 2013, to DNDi projects on leishmaniasis and Chagas disease.
GHIT Fund reinforces its support to DNDi leishmaniasis and Chagas disease projects
Caring for Kids with HIV and TB
Caring for Kids with HIV and TB
Sani sits in the doorway of her one-room house with her baby girl Mel in her arms. A pink sunset illuminates the Durban township of KwaMashu that unfolds below her clifftop house. She looks lovingly at Mel, then takes out a syringe and struggles to give the two-year-old,a medicine that is over 40% alcohol.
Caring for Kids with HIV and TB
‘We need to ensure that results of R&D are affordable and available to patients’
‘We need to ensure that results of R&D are affordable and available to patients’
Graeme BilbeGraeme Bilbe, Research & Development Director, DNDi [February 2017] ‘We need to ensure that results of R&D are affordable and available to patients’ DNDi’s R&D Director Graeme Bilbe looks back on 2016 and the exciting advances in DNDi’s portfolio, and explains what he sees as the biggest challenges facing the organization.
‘We need to ensure that results of R&D are affordable and available to patients’
R&D Status February 2017: DNDi Sleeping sickness programme
R&D Status February 2017: DNDi Sleeping sickness programme
Fexinidazole entered into the last stage of clinical development before potential submission to regulatory authorities in 2017 as the first new oral treatment for sleeping sickness, while SCYX-7158* moved to Phase II/III.
R&D Status February 2017: DNDi Sleeping sickness programme
See all news

Scientific Articles

See all scientific articles

Events

  • NTD Summit 2017 April 19-22, 2017 Geneva, Switzerland Bernard Pécoul, Executive Director, DNDi spoke at the event
  • ISNTD d3 2017

    Diagnostics, drug discovery and development

    May 16-17, 2017 London, United Kingdom Ivan Scandale, Project Manager, DNDi, will present on drug development approaches for filarial diseases.
  • WorldLeish 6

    6th World Congress on Leishmaniasis

    May 16-20, 2017 Toledo, Spain The WHO ColIaborating Centre for Leishmaniasis at the Instituto de Salud Carlos III, Madrid and the Drugs for Neglected Diseases initiative, Geneva have joined efforts to co-organize the WorldLeish-6 Congress.
See all events